Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054923 | 0.88 | CHRM1 (0.65) | CHRM1NAAASCN3AGRM2PTGS1 | |
| SCHEMBL508015 | 0.84 | CHRM1 (0.73) | CHRM1NAAACTSKNTRK1GRM2 | |
| SCHEMBL10054921 | 0.82 | CHRM1 (0.58) | CHRM1GRM2PTGS1SLC6A2SLC6A4 | |
| SCHEMBL508760 | 0.75 | CHRM1 (0.65) | CHRM1NAAACTSKNTRK1GRM2 | |
| SCHEMBL508070 | 0.73 | CHRM1 (0.60) | CHRM1NAAACTSKGRM2PTGS1 | |
| SCHEMBL509782 | 0.73 | CHRM1 (0.60) | CHRM1NAAACTSKGRM2PTGS1 | |
| SCHEMBL508066 | 0.71 | CHRM1 (0.94) | CHRM1NAAASCN3AGRM2PTGS1 | |
| SCHEMBL508022 | 0.69 | CHRM1 (0.73) | CHRM1NAAACTSKGRM2PTGS1 | |
| SCHEMBL508569 | 0.68 | CHRM1 (0.64) | CHRM1SCN3AGRM2PTGS1SLC6A2 | |
| SCHEMBL507656 | 0.68 | CHRM1 (0.81) | CHRM1GRM2PTGS1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | NOX5, MT-ND5, NQO1 | CHRM1 1375/4885NAAA 703/4885CTSK 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.